Opinion: Is A Cure for HIV/AIDS Possible?
Salter, J.D. & Smith, H.C. (2018) Modeling the Embrace of a Mutator: APOBEC Selection of Nucleic Acid Ligand. Trends in Biochemical Sciences. In press
Bennett, R.P., Salter, J.D., Smith, H.C. (2018) A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation. Trends in Molecular Medicine Published online March 30, 2018 PMID:29609878. Review
Polevoda, B., Joseph, R., Friedman, A.E., Bennett, R.P., Greiner, R., De Zoysa, T., Stewart, R.A., Smith, H.C. (2017) DNA Mutagenic Activity and Capacity for HIV-1 Restriction of the Cytidine Deaminase APOBEC3G Depends on Whether DNA or RNA Binds to Tyrosine 315. J. Biol. Chem., 292:8642-56.
Smith, H.C. (2017) RNA Binding to APOBEC Deaminases, Not Simply a Substrate for C to U Editing.RNA Biol. 14:1153-65.
Hilimire, T.A., Chamberlain, J.M., Anokhina. V, Bennett, R.P., Swart, O., Myers, J.R., Ashton, J.M., Stewart, R.A., Featherstone. A.L., Gates, K., Helms, E.D, Smith, H.C. Dewhurst, S., Miller, B.J. (2017) HIV-1 Frameshift RNA-Targeted Triazoles Inhibit Propagation of Replication-Competent and Multi-Drug-Resistant HIV in Human Cells. ACS Chem. Biol. 12:1674-82.
Bennett, R.P., Stewart, R.A., Hogan, P., Ptak, R.G., Mankowski, M.K., Hartman, T.L., Buckheit, R.W., Jr., Snyder, B.A., Salter, J.D., Morales, G.A., Smith, H.C. (2016) An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation. Antiviral Research 136:51-9 PMID:27825797
Salter, J.D., Bennett, R.P., Polevoda, B. and Smith, H.C. (2016) The APOBEC Protein Family United by Structure, Divergent in Function. Trends in Biochemical Sciences, Cell Press. 41:578-94 PMID:27283515
World AIDS Day Feature, aired December 3, 2015, Rochester Channel 8 News – Local biotech company finds HIV/AIDS breakthrough: OyaGen Inc. working towards clinical trials
World AIDS Day Feature, aired November 30, 2015 – Henrietta Medical Research Firm Working Toward HIV/AIDS Breakthrough
A&U America’s AIDS Magazine, October, 2015 – Talking “Cure”: What are the barriers to cure research? Part 1 of an interview with Dr. Harold Smith
A&U America’s AIDS Magazine, December 4, 2015 – High Bar: Have we limited cure research by approaching it through a treatment paradigm? Part 2 of an interview with Dr. Harold Smith
Profile in Adjacent Government, November 12, 2015 – Are we standing in our own way on the path to a cure for HIV /AIDS?
Smith HC, (2015) Starting Biotech from Scratch International Innovation. 185:82-85.
November 13, 2013 – U.S. Congresswoman Louise Slaughter visits OyaGen
October 2013 – Oyagen, Inc receives a third NIH grant as an R01 for the development of
methods for high throughput screening for compounds that prevent the cellular protein known as CBF beta from binding to and stabilizing the HIV Vif protein. Antagonist of
this interaction will prevent Vif from attacking our innate defense against HIV known as APOBEC.
September 16, 2013 – New York State Comptroller Thomas DiNapoli visits OyaGen
– Photos and story – Video coverage
July 12, 2013 – Assemblyman Harry B. Bronson visits OyaGen
June 6, 2013 – Senator Michael H. Ranzenhofer’s visit to OyaGen
News video featuring OyaGen – Biotech at the Rochester BioVenture Center
May 21, 2013 in the Strategic Health Resources LLC, Biotechnology Blog:
Fighting the Enemy at the Gates: A Small Biotech Company Battles to Provide New HIV Solutions as Long Term HIV Survivors Run Out Of Time
January 25, 2013 in HIV & HCV Haven:
Getting to the HAART of the matter: APOBECE3G A new target to cripple HIV
Oyagen, Inc receives a second NIH R21 grant for high throughput screening for compounds that activate the antiviral host defense activity of APOBEC3G entitled Development of a Novel HIV/AIDS Theraputic Activating the APOBEC3G Host Defense.
BluPrint Fund Award for Economic Development in UpState NY
Rochester, NY – Rochester Business Journal, January 8, 2010
Coverage of New York State Pension Fund Investment in OyaGen – September, 2010
State pension fund invests in Henrietta biotech firm
Rochester, NY – Democrat and Chronicle
OyaGen gets $500,000 from state retirement fund
Rochester, NY – Rochester Business Journal
Biotech Awarded Drug Discovery Grant
Rochester, NY – Channel 13 WOKR
Oyagen, Inc receives an NIH R21 grant for high throughput screening for compounds acting as Vif antagonist through the program announcement PAR08-024 Roadmap Molecular Libraries Initiative, entitled Development of a High Throughput Screen for Antagonists of Vif Dimerization.
Will health reform be shot in arm for biotech firms?
Rochester, NY – Democrat & Chronicle, April 2, 2010
OyaGen’s founder and CSO receives a Bill and Melinda Gates Foundation Award for his academic research.
Rochester, NY – URMC Press Release – October, 2009
Rochester, NY Named One of the Top 20 Tech Cities in the Country
Rochester, NY – Greater Rochester Enterprise advertisement, 2005
OyaGen blazing path toward anti-AIDS drug
Rochester, NY – Democrat & Chronicle, September 1, 2005
Study Holds Promise For New Way To Fight HIV
Rochester, NY – UR Press Release – September 1, 2005
OyaGen Scientific Advisor Board Meeting – photo
New York, NY – April, 2005
Television Interview with Dr
Rochester, NY – R News, Cable Channel 9, January, 2004
OyaGen Channel 13 Interview
Rochester, NY – WOKR13.TV – News Source 13, January, 2004
Rochester Start-Up Offers Groundbreaking Discovery in HIV Research
Rochester, NY – OyaGen Company Press Release
UR Invests in Anti-HIV Startup
Rochester, NY – Democrat & Chronicle, January 12, 2004
Publications from OyaGen
Smith HC, (2015) Starting Up the Road to Invention. International Innovation. 185:82-85.
Salter JD, Morales GA, Smith HC (2014) Structural insights for HIV-1 therapeutic strategies targeting Vif Trends in Biochemical Sciences September 2014. doi: 10.1016/j.tibs.2014.07.001
Mariel Selbovitz & OyaGen Community Access Board Member David Miller (2014)
The Deeper End of the Ocean: Host restrictive factors create research excitement.
A&U: America’s Aids Magazine 23 (232). p. 52
Prohaska K, Bennett RP, Salter JD, Smith HC (2014) The multifaceted roles of RNA binding in APOBEC cytidine deaminase functionsWIREs RNA 2014. doi: 10.1002/wrna.1226
Smith HC (2013) Curing Academic/Industry Ills: A National Biotech Policy Might Be the Best Solution. Genetic Engineering & Biotechnology News, November 15, 2013, 33:20
Smith HC (2011) APOBEC3G: a double agent in defense. Trends in Biochemical Sciences 2011, 36:5, pp. 239-244
Miller JH, Presnyak V, Smith HC (2007) The dimerization domain of HIV-1 viral infectivity factor Vif is required to block APOBEC3G incorporation with virions. Retrovirology 2007, 4:81